Director-linked funds at Veradermics (MANE) convert preferred and buy shares
Rhea-AI Filing Summary
Veradermics, Inc. director and 10% owner Patrick G. Enright reported indirect conversions and purchases of common stock. On February 5, 2026, Series B and Series C Convertible Preferred Stock automatically converted into 1,236,631 and 1,171,121 shares of common stock, respectively, on a 10.067-for-1 basis immediately before the closing of the company’s initial public offering, with no additional consideration.
Entities affiliated with Enright then bought 192,647 and 882,353 common shares at $17 per share, held through Longitude Venture Partners V, L.P. and Longitude 103.8 East, L.P., where voting and investment power is shared and beneficial ownership is disclaimed beyond pecuniary interests. On February 3, 2026, Enright also received a direct stock option for 45,131 shares at a $17 exercise price, vesting in full on February 3, 2027.
Positive
- None.
Negative
- None.